Longevity pathways (MTOR, SIRT, insulin/IGF-1) as key modulatory targets on aging and neurodegeneration

Current Topics in Medicinal Chemistry

Volumn 15, Issue 21, 2015, Pages 2116-2138

  Mazucanti, Caio Henrique ^a   Cabral Costa, João Victor ^a   Vasconcelos, Andrea Rodrigues ^a   Andreotti, Diana Zukas ^a   Scavone, Cristoforo ^a   Kawamoto, Elisa Mitiko ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aging; Insulin; Insulin like growth factor 1; MTOR; Neurodegenerative diseases; Sirtuin

Indexed keywords

CURCUMIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SOMATOMEDIN; TRANSCRIPTION FACTOR FKHR; MTOR PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CALORIC RESTRICTION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; LONGEVITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES;

AGING; ANIMALS; BRAIN; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 84939797569     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150610125715     Document Type: Article

References (316)

1. [1] Hoyert, D.L.; Xu, J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep., 2012, 61(6), 1-51.
2. [2] Yu, B.P. Aging and oxidative stress: modulation by dietary restriction. Free Rad. Biol. Med., 1996, 21, 651-658.
3. [3] Tosato, M.; Zamboni, V.; Ferrini, A.; Cesari, M. The aging process and potential interventions to extend life expectancy. Clin. Interv. Aging, 2007, 2, 401-412.
4. [4] Langa, K.M.; Levine, D.A. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA, 2014, 312(23), 2551-2561.
5. [5] Gkikas, I.; Petratou, D.; Tavernarakis, N. Longevity pathways and memory aging. Front. Genet., 2014, 5: 1-10.
6. [6] Barco, A.; Bailey, C.H.; Kandel, E.R. Common molecular mechanisms in explicit and implicit memory. J. Neurochem., 2006, 97, 1520-1533.
7. [7] Kauffman, A.L.; Ashraf, J.M.; Corces-Zimmerman, M.R.; Landis, J.N.; Murphy, C.T. Insulin signaling and dietary restriction differentially influence the decline of learning and memory with age. PLoS Biol., 2010, 8(5), e1000372.
8. [8] Brown, R.C.; Lokwood, A.H.; Sonawane, B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect., 2005, 113, 1250–1256.
9. [9] Herskovits, A.Z.; Guarente, L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res., 2013, 23, 746-758.
10. [10] Ehrnhoefer, D.E.; Wong, B.K.; Hayden, M.R. Convergent pathogenic pathways in Alzheimer’s and Huntington’s diseases: shared targets for drug development. Nat. Rev. Drug Discov., 2011, 10, 853-867.
11. [11] McGeer, P.L.; McGeer, E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev., 1995, 21(2), 195–218.
12. [12] Monsonego, A.; Weiner, H.L. Immunotherapeutic approaches to Alzheimer's disease. Science, 2003, 302(5646), 834–838.
13. [13] Donmez, G.; Outeiro, T. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol. Med., 2013, 5, 344-352.
14. [14] Miller, D.B.; O'Callaghan, J.P. Biomarkers of Parkinson's disease (PD): Present and future. Metabolism, 2014, DOI: 10.1016/j.metabol.2014.10.030.
15. [15] Martin, B.; Golden, E.; Keselman, A.; Stone, M.; Mattson, M.P.; Egan, J.M.; Maudsley, S. Therapeutic perspectives for the treatment of Huntington´s disease: treating the whole body. Histol. Histopathol., 2008, 23(2), 237-250.
16. [16] Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C.N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 2006, 127, 59-69.
17. [17] Duan, W.; Jiang, M.; Jin, J. Metabolism in HD: still a relevant mechanism? Mov. Disord., 2014, 29(11), 1366-1374.
18. [18] Trushina, E.; Dyer, R.B.; Badger, J.D.; Ure, D.; Eide, L.; Tran, D.D.; Vrieze, B.T.; Legendre-Guillemin, V.; McPherson, P.S.; Mandavilli, B.S.; Van Houten, B.; Zeitlin, S.; McNiven, M.; Aebersold, R.; Hayden, M.; Parisi, J.E.; Seeberg, E.; Dragatsis, I.; Doyle, K.; Bender, A.; Chacko, C.; McMurray, C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol., 2004, 24, 8195-8209.
19. [19] Paraíso, A.F.; Mendes, K.L.; Santos, S.H.S. Brain activation of SIRT1: Role in Neuropathology. Mol. Neurobiol., 2013, 48, 681-689.
20. [20] Zhang, F.; Wang, S.; Gan, L.; Vosler, P.S.; Gao, Y.; Zigmond, M.J.; Chen, J. Protective effects and mechanisms of sirtuins in the nervous system. Prog. Neurobiol., 2011, 95(3), 373–395.
21. [21] Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; Rahmani, Z.; Krizus, A.; Mckenna-Yasek, D.; Cayabyab, A.; Gaston, S.M.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeldt, B.; van den Bergh, R.; Hung, W.Y.; Bird, T.; Deng, G.; Mulder, D.W.; Smyth, C.; Laing, N.G.; Soriano, E.; Pericak-Vance, M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown, R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362, 59-62.
22. [22] López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell, 2013,153(6), 1194-217.
23. [23] Heitman, J.; Movva, N.R.; Hall, M.N. Targets of cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 1991, 253, 905-909.
24. [24] Blagosklonny, M.K. M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging, 2013, 5, 490-494.
25. [25] Johnson, S.C.; Rabinovitch, P.S.; Kaeberlein, M. mTOR is a key modulator of ageing and age-related disease. Nature, 2013, 493, 338-345.
26. [26] Schmelzle, T.; Hall, M.N. TOR, a central controller of cell growth. Cell, 2000, 103, 253-262.
27. [27] Lamming, D.W.; Ye, L.; Astle, C.M.; Baur, J.A.; Sabatini, D.M.; Harrison, D.E. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell, 2013, 12, 712-718.
28. [28] Chakrabarti, P.; English, T.; Shi, J.; Smas, C.M.; Kandror, K.V. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes, 2010, 59, 775-781.
29. [29] Kaeberlein, M.; Kennedy, B.K. Hot topics in aging research: protein translation and TOR signaling. Aging Cell, 2011, 10, 185-190.
30. [30] Noda, T.; Ohsumi, Y. Homologue, controls autophagy in yeast Tor, a phosphatidylinositol kinase. J. Biol. Chem., 1998, 273, 3963-3966.
31. [31] Blommaart, E.F.C.; Luiken, J.J.F.P.; Blommaart, P.J.E.; van Woerkom, G.M.; Meijer, A.J. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem., 1995, 270, 2320-2326.
32. [32] Tang, S.J.; Reis, G.; Kang, H.; Gingras, A.C.; Sonenberg, N.; Schuman, E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Nat. Acad. Sci. U.S.A., 2002, 99, 467-472.
33. [33] Schratt, G.M.; Nigh, E.A.; Chen, W.G.; Wu, L.; Greenberg, M.E. BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinasedependent pathway during neuronal development. J. Neurosci., 2004, 24, 7366-7377.
34. [34] Gong, R.; Park, C.S.; Abbassi, N.R.; Tang, S.J. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J. Biol. Chem., 2006, 281, 18802-18815.
35. [35] Lee, C.C., Huang, C.C., Wu, M.Y., Hsu, K.S. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J. Biol. Chem., 2005, 280, 18543-18550.
36. [36] Vezina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot., 1975, 28, 721-726.
37. [37] Wang, C.; Yu, J.T.; Miao, D.; Wu, Z.C.; Tan, M.S.; Tan, L. Targeting the mTOR signaling network for Alzheimer´s disease therapy. Mol. Neurobiol., 2014, 49, 120-135.
38. [38] Kaeberlein, M.; Powers, R.W.; Steffen, K.K.; Westman, E.A.; Hu, D.; Dang, N.; Kerr, E.O.; Kennedy, B.K. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science, 2005, 310, 1193-1196.
39. [39] Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter, C.S.; Pahor, M.; Javors, M.A.; Fernandez, E.; Miller, R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009, 460, 392-395.
40. [40] Miller, R.A.; Harrison, D.E.; Astle, C.M.; Baur, J.A.; Boyd, A.R.; deCabo, R.; Fernandez, E.; Flurkey, K.; Javors, M.A.; Nelson, J.F.; Orihuela, C.J.; Pletcher, S.; Sharp, Z.D.; Sinclair, D.; Starnes, J.W.; Wilkinson, J.E.; Nadon, N.L.; Strong, R. Rapamycin but not resveratrol or simvastatin extends life span of genetically heterogeneous mice. J. Gerontol. A. Biol. Sci. Med. Sci., 2011, 66, 191-201.
41. [41] Wilkinson, J.E.; Burmeister, L.; Brooks, S.V.; Chan, C.; Friedline, S.; Harrison, D.E.; Hejtmancik, J.F.; Nadon, N.; Strong, R.; Wood, L.K.; Woodwards, M.A.; Miller, R.A. Rapamycin slows aging in mice. Aging Cell, 2012, 11, 675-682.
42. [42] Wu, J.J.; Liu, J.; Chen, E.B.; Wang, J.J.; Cao, L.; Narayan, N.; Fergusson, M.M.; Rovira, I.I.; Allen, M.; Springer, D.A.; Lago, C.U.; Zhang, S.; DuBois, W.; Ward, T.; deCabo, R.; Gavrilova, O.; Mock, B.; Finkel, T. Increased mammalian lifespan and a segmental and tissuespecific slowing of aging after genetic reduction of mTOR expression. Cell Rep., 2013, 4, 913-920.
43. [43] Miller, R.A.; Harrison, D.E.; Astle, C.M.; Fernandez, E.; Flurkey, K.; Han, M.; Javors, M.A.; Li, X.; Nadon, N.L.; Nelson, J.F.; Pletcher, S.; Salmon, A.B.; Sharp, Z.D.; Van Roekel, S.; Winkleman, L.; Strong, R. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and appears metabolicallu distinct from dietary restriction. Aging Cell, 2014, 13, 468-477.
44. [44] Leontieva, O.V.; Paszkiewicz, G.M.; Blagosklonny, M.V. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell, 2014, 13, 616-622.
45. [45] Kolosova, N.G.; Vitovtov, A.O.; Muraleva, N.A.; Akulov, A.E.; Stefanova, N.A.; Blagosklonny, M.V. Rapamycin suppresses brain aging in senescence-accelerated OXYS rats. Aging, 2013, 5, 474-484.
46. [46] Houde, V.P.; Festuccia, B.S.; Blanchard, P.G.; Bellmann, K.; Deshaiers, Y.; Marette, A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes, 2010, 59, 1338-1348.
47. [47] Tataranni, T.; Biondi, G.; Cariello, M.; Mangino, M.; Colucci, G.; Rutigliano, M.; Ditonno, P.; Schena, F.P.; Gesualdo, L.; Grandaliano, G. Rapamycin induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am. J. Transplant., 2011, 11, 1656-1664.
48. [48] Lamming, D.W.; Ye, L.; Katajisto, P..; Gonçalves, M.D.; Saitoh, M.; Stevens, D.M.; Davis, J.G.; Salmon, A.B.; Richardson, A.; Ahima, R.S.; Guertin, D.A.; Sabatini, D.M.; Baur, J.A. Rapamycininduced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science, 2012, 335: 1638-1643.
49. [49] Festuccia, W.T.; Blanchard, P.G.; Belchior, T.; Chimin, P.; Paschoal, V.A.; Magdalon, J.; Hirabara, S.M.; Simões, D.; St- Pierre, P.; Carpinelli, A.; Marette, A.; Deshaies, Y. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. Am. J. Physiol. Endocrinol. Metab., 2014, 306, 1046-1054.
50. [50] Fang, Y.; Westbrook, R.; Hill, C.; Boparai, R.; Arum, O.; Spong, A.; Wang, F.; Javors, M.A.; Chen, J.; Sun, L.Y.; Bartke, A. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab., 2013, 17, 456-462.
51. [51] Liu, Y.; Diaz, V.; Fernandez, E.; Strong, R.; Ye, L.; Baur, J.A.; Lamming, D.W.; Richardson, A.; Salmon, A.B. Rapamycininduced metabolic defects are reversible in both lean and obese mice. Aging, 2014, 6, 742-754.
52. [52] Schindler, C.E.; Partap, U.; Patchen, B.K.; Swoap, S.J. Chronic rapamycin treatment causes diabetes in male mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2014, 307, 434-443.
53. [53] Villalonga-Planells, R.; Coll-Mulet, L.; Martinez-Soler, F.; Castaño, E.; Acebes, J.J.; Gimenez-Bonafe, P.; Gil, J.; Tortosa, A. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoSOne, 2011, 6, 1-12.
54. [54] Burke, S.N.; Barnes, C.A. Neural plasticity in the ageing brain. Nat. Rev. Neurosci., 2006, 7, 30-40.
55. [55] Majumder, S.; Caccamo, A.; Medina, D.X.; Benavides, A.D.; Javors, M.A.; Kraig, E.; Strong, R.; Richardson, A.; Oddo, S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell, 2012, 11, 326-335.
56. [56] Halloran, J.; Hussong, S.A.; Burbank, R.; Podlutskaya, N.; Fischer, K.E.; Sloane, L.B.; Austad, S.N.; Strong, R.; Richardson, A.; Hart, M.J.; Galvan, V. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience, 2012, 223, 102-113.
57. [57] Ramaiah, R.; Lam, A.M. Postoperative cognitive dysfunction in the elderly. Anesthesiol. Clin., 2009, 27, 485-496.
58. [58] Coburn, M.; Fahlenkamp, A.; Zoremba, N.; Schaelte, G. Postoperative cognitive dysfunction: incidence and prophylaxis. Anesthesist., 2010, 59, 177-184.
59. [59] Zhao, L.; Wang, F.; Gui, B.; Hua, F.; Qian, Y. Prophylactic lithium alleviates postoperative cognition impairment by phosphorylating hippocampal glycogen synthase kinase-3β (Ser9) in aged rats. Exp. Ger., 2011, 46, 1031-1036.
60. [60] Cracco, J.B.; Serrano, P.; Moskowitz, S.I.; Bergold, P.J.; Sacktor, T.C. Protein synthesis-dependent LTP in isolated dendrites of CA1 pyramidal cells. Hippocampus, 2011, 15, 551-556.
61. [61] Parsons, R.G.; Gafford, G.M.; Helmstetter, F.J. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J. Neurosci., 2006, 26, 12977-12983.
62. [62] Blundell, J.; Kouser, M.; Powell, C.M. Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol. Learn. Mem., 2008, 90, 28-35.
63. [63] Stoica, L.; Zhu, P.J.; Huang, W.; Zhou, H.; Kozma, S.C.; Costa-Mattioli, M. Selective pharmacogenetic inhibition of mammalian target of rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 3791-3796.
64. [64] Lyu, D.; Yu, W.; Tang, N.; Wang R.; Zhao, Z.; Xie, F.; He, Y.; Du, H.; Chen, J. The mTOR signaling pathway regulates pain-related synaptic plasticity in rat entorhinal-hippocampal pathways. Mol. Pain, 2013, 9, 1-11.
65. [65] Krug, M.; Lossner, B.; Ott, T. Anisomycin blocks the late phase of long-term potentiation in the dentate gyrus of freely-moving rats. Brain. Res. Bull., 1984, 13, 39-42.
66. [66] Otani, S.; Marshall, C.J.; Tate, W.P.; Goddard, G.V.; Abraham, W.C. Maintenance of long-term potentiation in rat dentate gyrus requires protein synthesis but not messenger RNA synthesis immediately post-tetanization. Neuroscience, 1989, 28, 519-526.
67. [67] Stanton, P.K.; Sarvey, J.M. Blockade of long-term potentiation in rat hippocampal CA1 region by inhibitors of protein synthesis. J. Neurosci., 1984, 4, 3080-3088.
68. [68] Otani, S.; Roisin-Lallemand, M.P.; Ben-Ari, Y. Enhancement of extracellular protein concentrations during long-term potentiation in the rat hippocampus. Neuroscience, 1992, 47, 265-272.
69. [69] Barnes, C.A. Memory deficits associated with senescence: a neurophysiological and behavioural study in the rat. J. Comp. Physiol. Psych., 1979, 93, 74-104.
70. [70] Lynch, M.A.; Voss, K.L. Membrane arachidonic acid concentration correlates with age and induction of longterm potentiation in the dentate gyrus in the rat. Eur. J. Neurosci., 1994, 6, 1008-1014.
71. [71] Mullany, P.; Lynch, M.A. Changes in protein synthesis and synthesis of the synaptic vesicle protein, synaptophysin, in entorhinal cortex following induction of long-term potentiation in dentate gyrus: an age-related study in the rat. Neuropharmacology, 1997, 36, 973-980.
72. [72] Hoeffer, C.A.; Klann, E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosc., 2010, 33, 67-75.
73. [73] Yang, L.; Zhang, J.; Zheng, K.; Shen, H.; Chen, X. Long-term ginsenoside Rg1 supplementation improves age-related cognitive decline by promoting synaptic plasticity associated protein expression in C57BL/6J mice. J. Gerontol. A. Biol. Sci. Med. Sci., 2014, 69, 282-294.
74. [74] Kawamoto, E.M.; Vivar, C.; Camandola, S. Physiology and pathology of calcium signaling in the brain. Front. Pharmacol., 2012, 13, 1-17.
75. [75] Gant, J.C.; Chen, K.C.; Norris, C.M.; Kadish, I.; Thibault, O.; Blalock, E.M.; Porter, N.M.; Landfield, P.W. Disrupting function of FK506-binding protein 1b/12.6 induces the Ca2+-dysregulation aging phenotype in hippocampal neurons. J. Neurosci., 2011, 31, 1693-1703.
76. [76] Mattson, M.P.; Duan, W.; Guo, Z. Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J. Neurochem., 2003, 84, 417-431.
77. [77] Kenyon, C.; Chang, J.; Gensch, E.; Rudner, A.; Tabtiang, R. A Celegans mutant that lives twice as long as wild type. Nature, 1993, 366, 461-464.
78. [78] Brown-Borg, H.M.; Borg, K.E.; Meliska, C.J.; Bartke, A. Dwarf mice and the ageing process. Nature, 1996, 384, 33.
79. [79] Milman, S.; Atzmon, G.; Huffman, D.M.; Wan, J.; Crandall, P.; Cohen, P.; Barzilai, N. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell, 2014, 13, 769-771.
80. [80] Wu, P.; Jiang, C.; Shen, Q.; Hu, Y. Systematic gene expression profile of hypothalamus in calorie-restricted mice implicates the involvement of mTOR signaling in neuroprotective activity. Mech. Ageing Develop., 2009, 130, 602-610.
81. [81] Jia, K.; Chen, D.; Riddle, D.L. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development, 2004, 131, 3897-3906.
82. [82] Partridge, L.; Alic, N.; Bjedov, I.; Piper, M.D. Ageing in Drosophila: the role of the insulin/Igf and TOR signaling network. Exp. Gerontol., 2011, 46, 376-381.
83. [83] Fontana, L.; Partridge, L.; Longo, V.D. Extending healthy life span-from yeast to humans. Science, 2010, 328, 321–326.
84. [84] Kenyon, C.J. The genetics of aging. Nature, 2010, 464, 504-512.
85. [85] Yang, F.; Chu, X.; Yin, M.; Liu, X.; Yuan, H. mTOR and autophagy in normal brain aging and caloric restriction ameliorating age-related cognition deficits. Behav. Brain Res., 2014, 264, 82-90.
86. [86] O' Neill, C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. Exp. Gerontol., 2013, 48(7), 647-53.
87. [87] Iyer, A.M.; van Scheppingen, J.; Milenkovic, I.; Anink, J.J.; Adle- Biassette, H.; Kovacs, G.G.; Aronica, E. mTOR Hyperactivation in down syndrome hippocampus appears early during development. J. Neuropathol. Exp. Neurol., 2014, 73(7), 671-83.
88. [88] Caccamo, A.; Magrì, A.; Medina, D.X.; Wisely, E.V.; López- Aranda, M.F.; Silva, A.J.; Oddo, S. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell, 2013, 12(3), 370-80.
89. [89] Tang, Z.; Bereczki, E.; Zhang, H.; Wang, S.; Li, C.; Ji, X.; Branca, R.M.; Lehtiö, J.; Guan, Z.; Filipcik, P.; Xu, S.; Winblad, B.; Pei, J.J. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J. Biol. Chem., 2013, 288(22), 15556-70.
90. [90] Zhu, Z.; Yan, J.; Jiang, W.; Yao, X.G.; Chen, J.; Chen, L.; Li, C.; Hu, L.; Jiang, H.; Shen, X. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β -amyloid production and clearance. J. Neurosci., 2013, 33(32), 13138-49.
91. [91] Ramírez, A.E.; Pacheco, C.R.; Aguayo, L.G.; Opazo, C.M. Rapamycin protects against Aβ-induced synaptotoxicity by increasing presynaptic activity in hippocampal neurons. Biochim. Biophys. Acta, 2014, 1842(9), 1495-501.
92. [92] Caccamo, A.; De Pinto, V.; Messina, A.; Branca, C.; Oddo, S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J. Neurosci., 2014, 34(23), 7988-98.
93. [93] Heras-Sandoval, D.; Pérez-Rojas, J.M.; Hernández-Damián, J.; Pedraza-Chaverri, J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal., 2014, 26(12), 2694-2701.
94. [94] Avrahami, L.; Farfara, D.; Shaham-Kol, M.; Vassar, R.; Frenkel, D.; Eldar-Finkelman, H. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J. Biol. Chem., 2013, 288(2), 1295-306.
95. [95] Steele, J.W.; Kim, S.H.; Cirrito, J.R.; Verges, D.K.; Restivo, J.L.; Westaway, D.; Fraser, P.; Hyslop, P.S.; Sano, M.; Bezprozvanny, I.; Ehrlich, M.E.; Holtzman, D.M.; Gandy, S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol. Neurodegener., 2009, 4, 51.
96. [96] Steele, J.W.; Lachenmayer, M.L.; Ju, S.; Stock, A.; Liken, J.; Kim, S.H.; Delgado, L.M.; Alfaro, I.E.; Bernales, S.; Verdile, G.; Bharadwaj, P.; Gupta, V.; Barr, R.; Friss, A.; Dolios, G.; Wang, R.; Ringe, D.; Fraser, P.; Westaway, D.; St George-Hyslop, P.H.; Szabo, P.; Relkin, N.R.; Buxbaum, J.D.; Glabe, C.G.; Protter, A.A.; Martins, R.N.; Ehrlich, M.E.; Petsko, G.A.; Yue, Z.; Gandy, S. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol. Psychiatry, 2013, 18(8), 889-97.
97. [97] Grossi, C.; Rigacci, S.; Ambrosini, S.; Ed Dami, T.; Luccarini, I.; Traini, C.; Failli, P.; Berti, A.; Casamenti, F.; Stefani, M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLoS One, 2013, 8(8), e71702.
98. [98] Yamamoto, N.; Tanida, M.; Kasahara, R.; Sobue, K.; Suzuki, K. Leptin inhibits amyloid β -protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway. J. Neurochem., 2014, 131(3), 323-32.
99. [99] Wang, Y.; Wang, Y.X.; Liu, T.; Law, P.Y.; Loh, H.H.; Qiu, Y.; Chen, H.Z. μ-Opioid Receptor Attenuates Aβ Oligomers-Induced Neurotoxicity Through mTOR Signaling. CNS Neurosci. Ther., 2015, 21(1), 8-14.
100. [100] Shen, Y.F.; Tang, Y.; Zhang, X.J.; Huang, K.X.; Le, W.D. Adaptive changes in autophagy after UPS impairment in Parkinson's disease. Acta Pharmacol. Sin., 2013, 34(5), 667-73.
101. [101] Jiang, T.F.; Zhang, Y.J.; Zhou, H.Y.; Wang, H.M.; Tian, L.P.; Liu, J.; Ding, J.Q.; Chen, S.D. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. J. Neuroimmune Pharmacol., 2013, 8(1), 356-69.
102. [102] Fragkouli, A.; Doxakis, E. miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front. Cell. Neurosci., 2014, 8, 182.
103. [103] Wakita, S.; Izumi, Y.; Nakai, T.; Adachi, K.; Takada-Takatori, Y.; Kume, T.; Akaike, A. Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of rapamycin signaling pathway. Neuropharmacology, 2014, 77, 39-48.
104. [104] Xu, Y.; Liu, C.; Chen, S.; Ye, Y.; Guo, M.; Ren, Q.; Liu, L.; Zhang, H.; Xu, C.; Zhou, Q.; Huang, S.; Chen, L. Activation of AMPK and inactivation of Akt result in suppression of mTORmediated S6K1 and 4EBP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Cell Signal., 2014, 26(8), 1680-9.
105. [105] Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J.E.; Luo, S.; Oroz, L.G.; Scaravilli, F.; Easton, D.F.; Duden, R.; O'Kane, C.J.; Rubinsztein, D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet., 2004, 36(6), 585-95.
106. [106] Kreiner, G.; Bierhoff, H.; Armentano, M.; Rodriguez-Parkitna, J.; Sowodniok, K.; Naranjo, J.R.; Bonfanti, L.; Liss, B.; Schütz, G.; Grummt, I.; Parlato, R. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ., 2013, 20(11), 1455-64.
107. [107] Proenca, C.C.; Stoehr, N.; Bernhard, M.; Seger, S.; Genoud, C.; Roscic, A.; Paganetti, P.; Liu, S.; Murphy, L.O.; Kuhn, R.; Bouwmeester, T.; Galimberti, I. Atg4b-dependent autophagic flux alleviates Huntington's disease progression. PLoS One, 2013, 8(7), e68357.
108. [108] Zhang, X.; Li, L.; Chen, S.; Yang, D.; Wang, Y.; Zhang, X.; Wang, Z.; Le, W. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy, 2011, 7(4), 412-25.
109. [109] Ching, J.K.; Elizabeth, S.V.; Ju, J.S.; Lusk, C.; Pittman, S.K.; Weihl, C.C. mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum. Mol. Genet., 2013, 22(6), 1167-79.
110. [110] Saxena, S.; Roselli, F.; Singh, K.; Leptien, K.; Julien, J.P.; Gros- Louis, F.; Caroni, P. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron, 2013, 80(1), 80-96.
111. [111] Bernard-Marissal, N.; Sunyach, C.; Marissal, T.; Raoul, C.; Pettmann, B. Calreticulin levels determine onset of early muscle denervation by fast motoneurons of ALS model mice. Neurobiol. Dis., 2015, 73, 130-136.
112. [112] Watanabe, S.; Hayakawa, T.; Wakasugi, K.; Yamanaka, K. Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death Dis., 2014, 5, e1497.
113. [113] Haigis, M.C.; Sinclair, D.A. Mammalian Sirtuins: biological insights and disease relevance. Annu. Rev. Pathol., 2010, 5, 253-295.
114. [114] Frye, R. Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-like Biochem. Biophys. Res. Commun., 2000, 273, 793-798.
115. [115] Merksamer, P.; Liu, Y.; He, W.; Hirschey, M.D.; Chen, D.; Verdin, E. The sirtuins, oxidative stress and aging: an emerging link. Aging, 2013, 5, 144-150.
116. [116] Kaeberlein, M.; McVey, M.; Guarente, L. The SIR2/3/4 coplex and SIR2 alone promote longevity in Sacharomyces cerevisae by two different mechanisms. Genes Dev., 1999, 13, 2570-2580.
117. [117] Jiang, M.; Wang, J.; Fu, J.; Du, L.; Jeong, H.; West, T.; Xiang, L.; Peng, Q.; Hou, Z.; Cai, H.; Seredenina, T.; Arbez, N.; Zhu, S.; Sommers, K.; Qian, J.; Zhang, J.; Mori, S.; Yang, X.W.; Tamashiro, K.L.; Aja, S.; Moran, T.H.; Luthi-Carter, R.; Martin, B.; Maudsley, S.; Mattson, M.P.; Cichewicz, R.H.; Ross, C.A.; Holtzman, D.M.; Krainc, D.; Duan, W. Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets. Nat. Med., 2011, 18, 153–158.
118. [118] Rine, J.; Herskowitz, I. Four Genes Responsible for a Position Effect on Expression From HML and HMR in Saccharomyces cerevisiae. Genetics, 1987, 1, 9-22.
119. [119] Verdin, E.; Hirschey, M.; Finley, L.; Haigis, M.C. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci., 2010, 35, 669-675.
120. [120] Du, J.; Zhou, Y.; Su, X.; Yu, J.J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J.H.; Choi, B.H.; He, B.; Chen, W.; Zhang, S.; Cerione, R.A.; Auwerx, J.; Hao, Q.; Lin, H. Sirt5 is a NADdependent protein lysine demalonylase and desuccinylase. Science, 2011, 334, 806–809.
121. [121] Ramadori, G.; Lee, C.; Bookout, A.; Lee, S.; Williams, K.W.; Anderson, J.; Elmquist, J.K.; Coppari, R. Brain SIRT1: anatomical distribution and regulation by energy availability. J. Neurosci., 2008, 28, 9989-9996.
122. [122] Hall, J.A.; Domini, J.E.; Lee, Y.; Puigserver, P. The sirtuin family’s role in aging and age-associated pathologies. J. Clin. Invest., 2013, 123, 973–979.
123. [123] Haigis, M.C.; Mostoslavsky, R.; Haigis, K.M.; Fahie, K.; Christodoulou, D.C.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Karow, M.; Blander, G.; Wolberger, C.; Prolla, T.A.; Weindruch, R.; Alt, F.W.; Guarente, L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells. Cell, 2006, 126, 941-954.
124. [124] Peng, C.; Lu, Z.; Xie, Z.; Cheng, Z.; Chen, Y.; Tan, M.; Luo, H.; Zhang, Y.; He, W.; Yang, K.; Zwaans, B.M.; Tishkoff, D.; Ho, L.; Lombard, D.; He, T.C.; Dai, J.; Verdin, E.; Ye, Y.; Zhao, Y. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell Proteomics, 2011, 10, M111.012658.
125. [125] Rahman, S.; Islam, R. Mammalian Sirt1: insights on its biological functions. Cell Commun. Signal., 2011, 9, 11.
126. [126] Giblin, W.; Skinner, M.E.; Lombard, D.B. Sirtuins: guardians of mammalian healthspan. Trends Genet., 2014, 7, 271-286.
127. [127] Herranz, D.; Muñoz-Martin, M.; Cañamero, M.; Mulero, F.; Martinez-Pastor, B.; Fernandez-Capetillo, O.; Serrano, M. Sirt1 improves healthy ageing and protects from metabolic syndromeassociated cancer. Nat. Commun., 2010, 1, 3.
128. [128] Jeong, H.; Cohen, D.E.; Cui, L.; Supinski, A.; Savas, J.N.; Mazzulli, J.R.; Yates, J.R.; Bordone, L.; Guarente, L.; Krainc, D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med., 2012, 18, 159–165.
129. [129] Satoh, A.; Brace, C.S.; Rensing, N.; Cliften, P.; Wozniak, D.F.; Herzog, E.D.; Yamada, K.A.; Imai, S. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab., 2013, 18, 416–430.
130. [130] Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100, 1512–1521.
131. [131] Mercken, E.M.; Hu, J.; Krzysik-Walker, S.; Wei, M.; Li, Y.; McBurney, M.W.; de Cabo, R.; Longo, V.D. SIRT1 but not its increased expression is essential for lifespan extension in caloricrestricted mice. Aging Cell, 2014, 13, 193–196.
132. [132] Chen, D.; Bruno, J.; Easlon, E.; Lin, S.J.; Cheng, H.L.; Alt, F.W.; Guarente, L. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev., 2008, 22, 1753–1757.
133. [133] Speakman, J.R.; Mitchell, S.E. Caloric restriction. Mol. Aspects Med., 2011, 32, 159–221.
134. [134] Guarente, L. Calorie restriction and sirtuins revisited. Genes Dev., 2013, 27, 2072–2085.
135. [135] Kume, S.; Uzu, T.; Horiike, K.; Chin-Kanasaki, M.; Isshiki, K.; Araki, S.; Sugimoto, T.; Haneda, M.; Kashiwagi, A.; Koya, D. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest., 2010, 120, 1043–1055.
136. [136] Rose, G.; Datom S.; Altomare, K.; Bellizzi, D.; Garasto, S.; Greco, V.; Passarino, G.; Feraco, E.; Mari, V.; Barbi, C.; BonaFe, M.; Franceschi, C.; Tan, Q.; Boiko, S.; Yashin, A.I.; De Benedictis, G. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp. Gerontol., 2003, 38, 1065-1070.
137. [137] Halaschek-Wiener, J.; Amirabbasi-Beik, M.; Monfared, N.; Pieczyk, M.; Sailer, C.; Kollar, A.; Thomas, R.; Agalaridis, G.; Yamada, S.; Oliveira, L.; Collins, J.A.; Meneilly, G.; Marra, M.A.; Madden, K.M.; Le, N.D.; Connors, J.M.; Brooks-Wilson, A.R. Genetic variation in healthy oldest- old. PLoS ONE, 2009, 4, e6641.
138. [138] Lombard, D.B.; Zwaans, B.M. SIRT3: as simple as it seems? Gerontology, 2014, 60, 56–64.
139. [139] Brown, K.; Xie, S.; Qiu, X.; Mohrin, M.; Shin, J.; Liu, Y.; Zhang, D.; Scadden, D.T.; Chen, D. SIRT3 reverses aging-associated degeneration. Cell Rep., 2013, 3, 319–327.
140. [140] Aury-Landas, J.; Bougeard, G.; Castel, H.; Hernandez-Vargas, H.; Drouet, A.; Latouche, J.B.; Schouft, M.T.; Férec, C.; Leroux, D.; Lasset, C.; Coupier, I.; Caron, O.; Herceg, Z.; Frebourg, T.; Flaman, J.M. Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li–Fraumeni syndrome with brain tumours. Eur. J. Hum. Genet., 2013, 21, 1369-1376.
141. [141] Kanfi, Y.; Naiman, S.; Amir, G.; Peshti, V.; Zinman, G.; Nahum, L.; Bar-Joseph, Z.; Cohen, H.Y. The sirtuin SIRT6 regulates lifespan in male mice. Nature, 2012, 483, 218-221.
142. [142] Xiao, C.; Kim, H.S.; Lahusen, T.; Wang, R.H.; Xu, X.; Gavrilova, O.; Jou, W.; Gius, D.; Deng, C.X. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem., 2010, 285, 36776–36784.
143. [143] Beauharnois, J.M.; Bolivar, B.E.; Welch, J.T. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol. Biosyst., 2013, 9, 1789–1806.
144. [144] Kuro-o, M. Klotho and the aging process. Korean J. Intern. Med., 2011, 26: 113-122.
145. [145] Yuan, Q.; Zhou, Q.; Liu, D.; Yu, L.; Zhan, L.; Li, X.J.; Peng, H.Y.; Zhang, X.L.; Yuan, X.C. Advanced glycation end-products impair Na⁺/K⁺-ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway. Clin. Exp. Pharmacol. Physiol., 2014, 41, 127-133.
146. [146] Mattson, M.P.; Calabrese, E.J. Hormesis: A Revolution in Biology, Toxicology and Medicine, Springer-Verlag New York LLC: New York, 2010.
147. [147] Mattson, M.; Liu, D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med., 2002, 2, 215-231.
148. [148] Kawamoto, E.M.; Munhoz, C.D.; Lepsch, L.B.; de Sa Lima, L.; Glezer, I.; Markus, R.P.; de Silva, C.L.; Camarini, R.; Marcourakis, T.; Scavone, C. Age-related changes in cerebellar phosphatase-1 reduce Na,K-ATPase activity. Neurobiol. Aging, 2008, 29, 1712-1720.
149. [149] Ristow, M.; Zarse, K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol., 2010, 45, 410-418.
150. [150] Dong, Y.; Liu, N.; Xiao, Z.; Sun, T.; Wu, S.; Sun, W.; Xu, Z. Yuan, H. Renal Protective Effect of Sirtuin 1. J. Diabetes Res., 2014, 2014, 843786.
151. [151] Jang, J.H.; Surh, Y.J. Protective effect of resveratrol on β-amyloidinduced oxidative PC12 cell death. Free Radic. Biol. Med., 2003, 34, 1100-1110.
152. [152] Karuppagounder, S.S.; Pinto, J.T.; Xu, H.; Chen, H.L.; Beal, M.F.; Gibson, G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int., 2009, 54, 111-118.
153. [153] Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; Puigserver, P.; Sinclair, D.A.; Tsai, L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophiclateral sclerosis. EMBO J., 2007, 26, 3169-3179.
154. [154] Anekonda, T.S.; Reddy, P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem., 2006, 96(2), 305–313.
155. [155] Zhou, Y.; Su, Y.; Li, B.; Liu, F.; Ryder, J.W.; Wu, X.; Gonzalez- DeWhitt, P.A.; Gelfanova, V.; Hale, J.E.; May, P.C.; Paul, S.M.; Ni, B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science, 2003, 302, 1215-1217.
156. [156] Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23(12), 2369–2380.
157. [157] Qin, W.; Chachich, M.; Lane, M.; Roth, G.; Bryant, M.; de Cabo, R.; Ottinger, M.A.; Mattison, J.; Ingram, D.; Gandy, S.; Pasinetti, G.M. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis., 2006, 10(4), 417–422.
158. [158] Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; Meyers, D.; Cole, P.A.; Ott, M.; Gan, L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 2010, 67, 953-966.
159. [159] Li, Y.; Xu, W.; McBurney, M.W.; Longo, V.D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab., 2008, 8, 38-48.
160. [160] Donmez, G; Arum, A; Chung C.Y.; Mclean, P. Lindquist, S; Guarente, L.; SIRT1 protects against α-sinuclein aggregation by activating molecular chaperones. J. Neurosci, 2012, 32, 124-132.
161. [161] Westerheide, S.D.; Anckar, J.; Stevens, S.M..; Sistonen, L.; Morimoto, R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 2009, 323, 1063-1066.
162. [162] Raynes, R.; Leckey, B.D.Jr.; Nguyen, K.; Westerheide, S.D. Heat shock and caloric restriction have a synergistic effect on the heat shock response in a sir2.1-dependent manner in Caenorhabditis elegans. J. Biol. Chem., 2012, 287, 29045-29053.
163. [163] Outeiro, T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G. Sirtuin 2 inhibitors rescue α-synucleinmediated toxicity in models of Parkinson’s disease. Science, 2007, 317, 516-519.
164. [164] Liu, L.; Arun, A.; Ellis, L.; Peritore, C.; Donmez, G. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J. Biol. Chem., 2012, 287, 32307-32311.
165. [165] Nemoto, S.; Fergusson, M.M.; Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem., 2005, 280(16), 16456–16460.
166. [166] Pallos, J.; Bodai, L.; Lukacsovich, T.; Purcell, J.M.; Steffan, J.S.; Thompson, L.M.; Marsh, J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum. Mol. Genet., 2008, 17, 3767-3775.
167. [167] Luthi-Carter, R.; Taylor, D.M.; Pallos, J.; Lambert, E.; Amore, A.; Parker, A.; Moffitt, H.; Smith, D.L.; Runne, H.; Gokce, O.; Kuhn, A.; Xiang, Z.; Maxwell, M.M.; Reeves, S.A.; Bates, G.P.; Neri, C.; Thompson, L.M.; Marsh, J.L.; Kazantsev, A.G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 7927-7932.
168. [168] Chopra, V.; Quinti, L.; Kim, J.; Vollor, L.; Narayanan, K.L.; Edgerly, C.; Cipicchio, P.M.; Lauver, M.A.; Choi, S.H.; Silverman, R.B.; Ferrante, R.J.; Hersch, S.; Kazantsev, A.G. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep., 2012, 2, 1492-1497.
169. [169] Bobrowska, A.; Donmez, G.; Weiss, A.; Guarente, L.; Bates, G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington’s disease phenotypes in vivo. PLoS One, 2012, 7, e34805.
170. [170] Taylor, D.M.; Balabadra, U.; Xiang, Z.; Woodman, B.; Meade, S.; Amore, A.; Maxwell, M.M.; Reeves, S.; Bates, G.P.; Luthi-Carter, R.; Lowden, P.A.; Kazantsev, A.G. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol., 2011, 6(6), 540-6.
171. [171] Fu, J.; Jin, J.; Cichewicz, R.H.; Hageman, S.A.; Ellis, T.K.; Xiang, L.; Peng, Q.; Jiang, M.; Arbez, N.; Hotaling, K.; Ross, C.A.; Duan, W. trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington disease. J. Biol. Chem., 2012, 287, 24460-24472.
172. [172] Wang, J.; Zhang, Y.; Tang, L.; Zhang, N.; Fan, D. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci. Lett., 2011, 503, 250-255.
173. [173] Yáñez, M.; Galán, L.; Matías-Guiu, J.; Vela, A.; Guerrero, A.; García, A.G. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res., 2011, 1423, 77-86.
174. [174] Han, S.; Choi, J.R.; Soon Shin, K.; Kang, S.J. Resveratrol upregulated heat shock proteins and extended the survival of G93ASOD1 mice. Brain Res., 2012, 1483, 112-117.
175. [175] Kiaei, M. Peroxisome proliferator-activated receptorgamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res., 2008, 2008, 418-765.
176. [176] Song, W.; Song, Y.; Kincaid, B.; Bossy, B.; Bossy-Wetzel, E. Mutant SOD1(G93A) triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1α. Neurobiol. Dis., 2013, 51, 72-81.
177. [177] Murphy, C.T.; Hu, P.J. Insulin-insulin-like growth factor signaling in C. elegans. WormBook, 2013, 26, 1-43.
178. [178] Park, C.R.; Seeley, R.J.; Craft, S.; Woods, S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav., 2000, 68(4), 509-514.
179. [179] Babri, S.; Badie, H. G.; Khamenei, S.; Seyedlar, M. O. Intrahippocampal insulin improves memory in a passive-avoidance task in male wistar rats. Brain Cogn., 2007, 64(1), 86-91.
180. [180] Haj-ali, V.; Mohaddes, G.; Babri, S.H. Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav. Neurosci., 2009, 123(6), 1309-1314.
181. [181] Moosavi, M.; Naghdi, N.; Maghsoudi, N.; Zahedi Asl, S. The effect of intrahippocampal insulin microinjection on spatial learning and memory. Horm. Behav., 2006, 50(5), 748-752.
182. [182] McNay, E.C.; Ong, C.T.; McCrimmon, R.J.; Cresswell, J.; Bogan, J.S.; Sherwin, R.S. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem., 2010, 93(4), 546-553.
183. [183] Stern, S.A.; Chen, D.Y.; Alberini, C.M. The effect of insulin and insulin-like growth factors on hippocampus- and amygdaladependent long-term memory formation. Learn. Mem., 2014, 21(10), 556-563.
184. [184] Rollero, A.; Murialdo, G.; Fonzi, S.; Garrone, S.; Gianelli, M.V.; Gazzerro, E.; Barreca, A.; Polleri, A. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology, 1998, 38(2), 73-79.
185. [185] Aleman, A.; Verhaar, H. J.; De Haan, E. H.; De Vries, W. R.; Samson, M. M.; Drent, M. L.; Van der Veen, E. A.; Koppeschaar, H. P. Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab., 1999, 84(2), 471-475.
186. [186] Dik, M.G.; Pluijm, S.M.; Jonker, C.; Deeg, D.J.; Lomecky, M.Z.; Lips, P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol. Aging, 2003, 24(4), 573-581.
187. [187] Landi, F.; Capoluongo, E.; Russo, A.; Onder, G.; Cesari, M.; Lulli, P.; Minucci, A.; Pahor, M.; Zuppi, C.; Bernabei, R. Free insulinlike growth factor-I and cognitive function in older persons living in community. Growth Horm. IGF Res., 2007, 17(1), 58-66.
188. [188] Bellar, D.; Glickman, E. L.; Juvancic-Heltzel, J.; Gunstad, J. Serum insulin like growth factor-1 is associated with working memory, executive function and selective attention in a sample of healthy, fit older adults. Neuroscience, 2011, 178, 133-137.
189. [189] Olefsky, J.M.; Nolan, J.J. Insulin resistance and non-insulindependent diabetes mellitus: cellular and molecular mechanisms. Am. J. Clin. Nutr., 1995, 61(4 Suppl), 980S-986S.
190. [190] Pessin, J.E.; Saltiel, A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest., 2000, 106(2), 165-169.
191. [191] Biddinger, S. B.; Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol., 2006, 68, 123-158.
192. [192] Plum, L.; Schubert, M.; Bruning, J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab., 2005, 16(2), 59-65.
193. [193] Russo, V.C.; Gluckman, P.D.; Feldman, E.L.; Werther, G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev., 2005, 26(7), 916-943.
194. [194] Aberg, N.D.; Brywe, K.G.; Isgaard, J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scientific World Journal, 2006, 6, 53-80.
195. [195] van der Heide, L.P.; Ramakers, G.M.; Smidt, M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol., 2006, 79(4), 205-221.
196. [196] Zhao, W.Q.; Alkon, D.L. Role of insulin and insulin receptor in learning and memory. Mol. Cell Endocrinol., 2001, 177(1-2), 125-134.
197. [197] Chiu, S.L.; Chen, C.M.; Cline, H.T. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron, 2008, 58(5), 708-719.
198. [198] Costello, D.A.; Claret, M.; Al-Qassab, H.; Plattner, F.; Irvine, E.E.; Choudhury, A I.; Giese, K.P.; Withers, D.J.; Pedarzani, P. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One, 2012, 7(2), e31124.
199. [199] Bluher, M.; Kahn, B.B.; Kahn, C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science, 2003, 299(5606), 572-4.
200. [160] Donmez, G; Arum, A; Chung C.Y.; Mclean, P. Lindquist, S; Guarente, L.; SIRT1 protects against α-sinuclein aggregation by activating molecular chaperones. J. Neurosci, 2012, 32, 124-132.
201. [161] Westerheide, S.D.; Anckar, J.; Stevens, S.M..; Sistonen, L.; Morimoto, R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 2009, 323, 1063-1066.
202. [162] Raynes, R.; Leckey, B.D.Jr.; Nguyen, K.; Westerheide, S.D. Heat shock and caloric restriction have a synergistic effect on the heat shock response in a sir2.1-dependent manner in Caenorhabditis elegans. J. Biol. Chem., 2012, 287, 29045-29053.
203. [163] Outeiro, T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G. Sirtuin 2 inhibitors rescue α-synucleinmediated toxicity in models of Parkinson’s disease. Science, 2007, 317, 516-519.
204. [164] Liu, L.; Arun, A.; Ellis, L.; Peritore, C.; Donmez, G. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J. Biol. Chem., 2012, 287, 32307-32311.
205. [165] Nemoto, S.; Fergusson, M.M.; Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem., 2005, 280(16), 16456–16460.
206. [166] Pallos, J.; Bodai, L.; Lukacsovich, T.; Purcell, J.M.; Steffan, J.S.; Thompson, L.M.; Marsh, J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum. Mol. Genet., 2008, 17, 3767-3775.
207. [167] Luthi-Carter, R.; Taylor, D.M.; Pallos, J.; Lambert, E.; Amore, A.; Parker, A.; Moffitt, H.; Smith, D.L.; Runne, H.; Gokce, O.; Kuhn, A.; Xiang, Z.; Maxwell, M.M.; Reeves, S.A.; Bates, G.P.; Neri, C.; Thompson, L.M.; Marsh, J.L.; Kazantsev, A.G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 7927-7932.
208. [168] Chopra, V.; Quinti, L.; Kim, J.; Vollor, L.; Narayanan, K.L.; Edgerly, C.; Cipicchio, P.M.; Lauver, M.A.; Choi, S.H.; Silverman, R.B.; Ferrante, R.J.; Hersch, S.; Kazantsev, A.G. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep., 2012, 2, 1492-1497.
209. [169] Bobrowska, A.; Donmez, G.; Weiss, A.; Guarente, L.; Bates, G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington’s disease phenotypes in vivo. PLoS One, 2012, 7, e34805.
210. [170] Taylor, D.M.; Balabadra, U.; Xiang, Z.; Woodman, B.; Meade, S.; Amore, A.; Maxwell, M.M.; Reeves, S.; Bates, G.P.; Luthi-Carter, R.; Lowden, P.A.; Kazantsev, A.G. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol., 2011, 6(6), 540-6.
211. [171] Fu, J.; Jin, J.; Cichewicz, R.H.; Hageman, S.A.; Ellis, T.K.; Xiang, L.; Peng, Q.; Jiang, M.; Arbez, N.; Hotaling, K.; Ross, C.A.; Duan, W. trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington disease. J. Biol. Chem., 2012, 287, 24460-24472.
212. [172] Wang, J.; Zhang, Y.; Tang, L.; Zhang, N.; Fan, D. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci. Lett., 2011, 503, 250-255.
213. [173] Yáñez, M.; Galán, L.; Matías-Guiu, J.; Vela, A.; Guerrero, A.; García, A.G. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res., 2011, 1423, 77-86.
214. [174] Han, S.; Choi, J.R.; Soon Shin, K.; Kang, S.J. Resveratrol upregulated heat shock proteins and extended the survival of G93ASOD1 mice. Brain Res., 2012, 1483, 112-117.
215. [175] Kiaei, M. Peroxisome proliferator-activated receptorgamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res., 2008, 2008, 418-765.
216. [176] Song, W.; Song, Y.; Kincaid, B.; Bossy, B.; Bossy-Wetzel, E. Mutant SOD1(G93A) triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1α. Neurobiol. Dis., 2013, 51, 72-81.
217. [177] Murphy, C.T.; Hu, P.J. Insulin-insulin-like growth factor signaling in C. elegans. WormBook, 2013, 26, 1-43.
218. [178] Park, C.R.; Seeley, R.J.; Craft, S.; Woods, S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav., 2000, 68(4), 509-514.
219. [179] Babri, S.; Badie, H. G.; Khamenei, S.; Seyedlar, M. O. Intrahippocampal insulin improves memory in a passive-avoidance task in male wistar rats. Brain Cogn., 2007, 64(1), 86-91.
220. [180] Haj-ali, V.; Mohaddes, G.; Babri, S.H. Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav. Neurosci., 2009, 123(6), 1309-1314.
221. [181] Moosavi, M.; Naghdi, N.; Maghsoudi, N.; Zahedi Asl, S. The effect of intrahippocampal insulin microinjection on spatial learning and memory. Horm. Behav., 2006, 50(5), 748-752.
222. [182] McNay, E.C.; Ong, C.T.; McCrimmon, R.J.; Cresswell, J.; Bogan, J.S.; Sherwin, R.S. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem., 2010, 93(4), 546-553.
223. [183] Stern, S.A.; Chen, D.Y.; Alberini, C.M. The effect of insulin and insulin-like growth factors on hippocampus- and amygdaladependent long-term memory formation. Learn. Mem., 2014, 21(10), 556-563.
224. [184] Rollero, A.; Murialdo, G.; Fonzi, S.; Garrone, S.; Gianelli, M.V.; Gazzerro, E.; Barreca, A.; Polleri, A. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology, 1998, 38(2), 73-79.
225. [185] Aleman, A.; Verhaar, H. J.; De Haan, E. H.; De Vries, W. R.; Samson, M. M.; Drent, M. L.; Van der Veen, E. A.; Koppeschaar, H. P. Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab., 1999, 84(2), 471-475.
226. [186] Dik, M.G.; Pluijm, S.M.; Jonker, C.; Deeg, D.J.; Lomecky, M.Z.; Lips, P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol. Aging, 2003, 24(4), 573-581.
227. [187] Landi, F.; Capoluongo, E.; Russo, A.; Onder, G.; Cesari, M.; Lulli, P.; Minucci, A.; Pahor, M.; Zuppi, C.; Bernabei, R. Free insulinlike growth factor-I and cognitive function in older persons living in community. Growth Horm. IGF Res., 2007, 17(1), 58-66.
228. [188] Bellar, D.; Glickman, E. L.; Juvancic-Heltzel, J.; Gunstad, J. Serum insulin like growth factor-1 is associated with working memory, executive function and selective attention in a sample of healthy, fit older adults. Neuroscience, 2011, 178, 133-137.
229. [189] Olefsky, J.M.; Nolan, J.J. Insulin resistance and non-insulindependent diabetes mellitus: cellular and molecular mechanisms. Am. J. Clin. Nutr., 1995, 61(4 Suppl), 980S-986S.
230. [190] Pessin, J.E.; Saltiel, A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest., 2000, 106(2), 165-169.
231. [191] Biddinger, S. B.; Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol., 2006, 68, 123-158.
232. [192] Plum, L.; Schubert, M.; Bruning, J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab., 2005, 16(2), 59-65.
233. [193] Russo, V.C.; Gluckman, P.D.; Feldman, E.L.; Werther, G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev., 2005, 26(7), 916-943.
234. [194] Aberg, N.D.; Brywe, K.G.; Isgaard, J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scientific World Journal, 2006, 6, 53-80.
235. [195] van der Heide, L.P.; Ramakers, G.M.; Smidt, M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol., 2006, 79(4), 205-221.
236. [196] Zhao, W.Q.; Alkon, D.L. Role of insulin and insulin receptor in learning and memory. Mol. Cell Endocrinol., 2001, 177(1-2), 125-134.
237. [197] Chiu, S.L.; Chen, C.M.; Cline, H.T. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron, 2008, 58(5), 708-719.
238. [198] Costello, D.A.; Claret, M.; Al-Qassab, H.; Plattner, F.; Irvine, E.E.; Choudhury, A I.; Giese, K.P.; Withers, D.J.; Pedarzani, P. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One, 2012, 7(2), e31124.
239. [199] Bluher, M.; Kahn, B.B.; Kahn, C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science, 2003, 299(5606), 572-4.
240. [243] McElwee, J.; Bubb, K.; Thomas, J.H. Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging Cell, 2003, 2, 111-21.
241. [244] Dong, M.Q.; Venable, J.D.; Au, N.; Xu, T.; Park, S.K.; Cociorva, D.; Johnson, J.R.; Dillin, A.; Yates, J.R. Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science, 2007, 317, 660-3.
242. [245] Morley, J.F.; Brignull, H.R.; Weyers, J.J.; Morimoto, R.I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 10417-22.
243. [246] Link, C. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 9368-72.
244. [247] Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; Yoshida, M.; Hashizume, Y.; Oda, T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun., 2006, 351, 602-11.
245. [248] Zhang, T.; Mullane, PC.; Periz, G.; Wang, J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum. Mol. Genet., 2011, 15-20(10), 1952-65.
246. [249] Boccitto, M.; Lamitina, T.; Kalb, R.G. Daf-2 signaling modifies mutant SOD1 toxicity in C. elegans. PLoS One, 2012, 7, e33494.
247. [250] Teixeira-Castro, A.; Ailion, M.; Jalles, A.; Brignull, H.R.; Vilaça, J.L.; Dias, N.; Rodrigues, P.; Oliveira, J.F.; Neves-Carvalho, A.; Morimoto, R.I.; Maciel, P. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum. Mol. Genet., 2011, 20(15), 2996-3009.
248. [251] Killick, R.; Scales, G.; Leroy, K.; Causevic, M.; Hooper, C.; Irvine, E.E.; Choudhury, A.I.; Drinkwater, L.; Kerr, F.; Al-Qassab, H.; Stephenson, J.; Yilmaz, Z.; Giese, K.P.; Brion, J. P.; Withers, D.J.; Lovestone, S. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem. Biophys. Res. Commun., 2009, 386(1), 257-262.
249. [252] Cohen, E.; Paulsson, J.F.; Blinder, P.; Burstyn-Cohen, T.; Du, D.; Estepa, G.; Adame, A.; Pham, H.M.; Holzenberger, M.; Kelly, J.W.; Masliah, E.; Dillin, A. Reduced IGF-1 signaling delays ageassociated proteotoxicity in mice. Cell, 2009, 139(6), 1157-1169.
250. [253] Freude, S.; Hettich, M.M.; Schumann, C.; Stohr, O.; Koch, L.; Kohler, C.; Udelhoven, M.; Leeser, U.; Muller, M.; Kubota, N.; Kadowaki, T.; Krone, W.; Schroder, H.; Bruning, J.C.; Schubert, M. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J., 2009, 23(10), 3315-3324.
251. [254] Steculorum, S.M.; Solas, M.; Brüning, J.C. The paradox of neuronal insulin action and resistance in the development of agingassociated diseases. Alzheimers Dement., 2014, 10(1 Suppl), S3-11.
252. [255] Zhao, W.Q.; Chen, H.; Quon, M.J.; Alkon, D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol., 2004, 490, 71–81.
253. [256] Arvanitakis, Z.; Wilson, R. S.; Bienias, J. L.; Evans, D. A.; Bennett, D. A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol., 2004, 61(5), 661-666.
254. [257] Haan, M.N. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol., 2006, 2(3), 159-166.
255. [258] Schrijvers, E.M.; Witteman, J.C.; Sijbrands, E.J.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology, 2010, 75(22), 1982-1987.
256. [259] de la Monte, S.M.; Wands, J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis., 2006, 9(2), 167-181.
257. [260] Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
258. [261] Pedersen, W.A.; Flynn, E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis., 2004, 17(3), 500-506.
259. [262] Carvalho, C.; Cardoso, S.; Correia, S.C.; Santos, R.X.; Santos, M.S.; Baldeiras, I.; Oliveira, C.R.; Moreira, P.I. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes, 2012, 61(5), 1234-1242.
260. [263] Carvalho, C.; Machado, N.; Mota, P.C.; Correia, S.C.; Cardoso, S.; Santos, R.X.; Santos, M. S.; Oliveira, C.R.; Moreira, P.I. Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies. J. Alzheimers Dis., 2013, 35(3), 623-635.
261. [264] Santos, T.O.; Mazucanti, C.H.Y.; Xavier, G.F.; Torrão, A.S. Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiology & Behavior, 2012, 107, 401-413.
262. [265] Ahtiluoto, S.; Polvikoski, T.; Peltonen, M.; Solomon, A.; Tuomilehto, J.; Winblad, B.; Sulkava, R.; Kivipelto, M. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology, 2010, 75(13), 1195-1202.
263. [266] Wang, K.C.; Woung, L.C.; Tsai, M.T.; Liu, C.C.; Su, Y.H.; Li, C.Y. Risk of Alzheimer's disease in relation to diabetes: a population- based cohort study. Neuroepidemiology, 2012, 38(4), 237-244.
264. [267] Crane, P.K.; Walker, R.; Hubbard, R.A.; Li, G.; Nathan, D.M.; Zheng, H.; Haneuse, S.; Craft, S.; Montine, T.J.; Kahn, S.E.; McCormick, W.; McCurry, S.M.; Bowen, J.D.; Larson, E.B. Glucose levels and risk of dementia. N. Engl. J. Med., 2013, 369(6), 540-548.
265. [268] Bassil, F.; Fernagut, P. O.; Bezard, E.; Meissner, W. G. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog. Neurobiol., 2014, 118, 1-18.
266. [269] Moloney, A.M.; Griffin, R.J.; Timmons, S.; O'Connor, R.; Ravid, R.; O'Neill, C. Defects in IGF-1 receptor, insulin receptor and IRS- 1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging, 2010, 31(2), 224-243.
267. [270] Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J. Alzheimers Dis., 2005, 7(1), 63-80.
268. [271] Aguirre, V.; Werner, E.D.; Giraud, J.; Lee, Y.H.; Shoelson, S.E.; White, M.F. Phosphorylation of Ser307 in insulin receptor substrate- 1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem., 2002, 277(2), 1531-1537.
269. [272] Sun, X.J.; Goldberg, J.L.; Qiao, L.Y.; Mitchell, J. J. Insulininduced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes, 1999, 48(7), 1359-1364.
270. [273] Pederson, T.M.; Kramer, D.L.; Rondinone, C.M. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes, 2001, 50(1), 24-31.
271. [274] Rui, L.; Aguirre, V.; Kim, J.K.; Shulman, G.I.; Lee, A.; Corbould, A.; Dunaif, A.; White, M.F. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest., 2001, 107(2), 181-189.
272. [275] Saad, M.J.; Araki, E.; Miralpeix, M.; Rothenberg, P.L.; White, M.F.; Kahn, C.R. of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J. Clin. Invest., 1992, 90(5), 1839-1849.
273. [276] Talbot, K.; Wang, H.Y.; Kazi, H.; Han, L.Y.; Bakshi, K.P.; Stucky, A.; Fuino, R.L.; Kawaguchi, K.R.; Samoyedny, A.J.; Wilson, R.S.; Arvanitakis, Z.; Schneider, J.A.; Wolf, B.A.; Bennett, D.A.; Trojanowski, J.Q.; Arnold, S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest., 2012, 122(4), 1316-1338.
274. [277] Correia, S.C.; Santos, R.X.; Perry, G.; Zhu, X.; Moreira, P.I.; Smith, M.A. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res. Rev., 2011, 10(2), 264-273.
275. [278] Kawamoto, E.M.; Scavone, C.; Mattson, M.P.; Camandola, S. Curcumin requires tumor necrosis factor alpha signaling to alleviate cognitive impairment elicited by lipopolysaccharide. Neurosignals, 2013, 21(1-2), 75-88.
276. [279] Ma, Q.L.; Yang, F.; Rosario, E.R.; Ubeda, O.J.; Beech, W.; Gant, D.J.; Chen, P.P.; Hudspeth, B.; Chen, C.; Zhao, Y.; Vinters, H.V.; Frautschy, S.A.; Cole, G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci., 2009, 29(28), 9078-9089.
277. [280] Zhao, W.Q.; De Felice, F.G.; Fernandez, S.; Chen, H.; Lambert, M.P.; Quon, M.J.; Krafft, G.A.; Klein, W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J., 2008, 22(1), 246-260.
278. [281] De Felice, F.G.; Vieira, M.N.; Bomfim, T.R.; Decker, H.; Velasco, P.T.; Lambert, M.P.; Viola, K.L.; Zhao, W.Q.; Ferreira, S.T.; Klein, W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(6), 1971-1976.
279. [282] Bomfim, T. R.; Forny-Germano, L.; Sathler, L. B.; Brito-Moreira, J.; Houzel, J. C.; Decker, H.; Silverman, M. A.; Kazi, H.; Melo, H. M.; McClean, P. L.; Holscher, C.; Arnold, S. E.; Talbot, K.; Klein, W. L.; Munoz, D. P.; Ferreira, S. T.; De Felice, F. G. An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest., 2012, 122(4), 1339-1353.
280. [283] Gasparini, L.; Gouras, G.K.; Wang, R.; Gross, R.S.; Beal, M.F.; Greengard, P.; Xu, H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci., 2001, 21(8), 2561-2570.
281. [284] Carro, E.; Trejo, J.L.; Gomez-Isla, T.; LeRoith, D.; Torres-Aleman, I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med., 2002, 8(12), 1390-1397.
282. [285] Carro, E.; Trejo, J.L.; Gerber, A.; Loetscher, H.; Torrado, J.; Metzger, F. Torres-Aleman, I. (2006). Therapeutic actions of insulinlike growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging, 2006, 27(9), 1250-1257.
283. [286] Johansson, P.; Aberg, D.; Johansson, J.O.; Mattsson, N.; Hansson, O.; Ahren, B.; Isgaard, J.; Aberg, N.D.; Blennow, K.; Zetterberg, H.; Wallin, A.; Svensson, J. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein- 3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38(9), 1729-1737.
284. [287] Trueba-Saiz, A.; Cavada, C.; Fernandez, A.M.; Leon, T.; Gonzalez, D.A.; Fortea Ormaechea, J.; Lleo, A.; Del Ser, T.; Nunez, A.; Torres- Aleman, I. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl. Psychiatry, 2013, 3, e330.
285. [288] Reger, M.A.; Watson, G.S.; Green, P.S.; Baker, L.D.; Cholerton, B.; Fishel, M.A.; Plymate, S.R.; Cherrier, M.M.; Schellenberg, G.D.; Frey, W.H.; Craft, S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloidbeta in memory-impaired older adults. J. Alzheimers. Dis., 2008, 13(3), 323-331.
286. [289] Reger, M.A.; Watson, G.S.; Green, P.S.; Wilkinson, C.W.; Baker, L.D.; Cholerton, B.; Fishel, M.A.; Plymate, S.R.; Breitner, J.C.; DeGroodt, W.; Mehta, P.; Craft, S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 2008, 70(6), 440-448.
287. [290] Kurochkin, I.V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci., 2001, 26(7), 421-425.
288. [291] Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E.A.; Frosch, M.P.; Eckman, C.B.; Tanzi, R.E.; Selkoe, D.J.; Guenette, S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A., 2003, 100(7), 4162-4167.
289. [292] Numao, a., Suzuki, K., Miyamoto, M., Miyamoto, T., Hirata, K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson´s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism. Relat. Disord., 2014, 20(2), 212-216.
290. [293] Picillo, M., Erro, R., Santangelo, G., Pivonello, R., Longo, K., Pivonello, C., Vitale, C., Amboni, M., Moccia, M., Colao, A., Barone, P., Pellecchia, M.T. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson´s disease. J. Neurol., 2013, 260(7): 1724-1730.
291. [294] Godau, J., Knauel, K., Weber, K., Brockmann, K., Maetzler, W., Binder, G., Berg, D. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch. Neurol., 2011, 68(7), 925-931.
292. [295] Chung, J.Y., Lee, S.J., Lee, S.H., Jung, Y.S., Ha, N.C., Seol, W., Park, B.J. Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease. Neurosignals, 2011, 19(2): 86-96.
293. [296] Offen, D.; Shtaif, B.; Hadad, D.; Weizman, A.; Melamed, E.; Gil- Ad, I. Protective effect of insulin-like-growth-factor-1 against dopamine- induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci. Lett., 2001, 316(3), 129-132.
294. [297] Kao, S.Y. Rescue of synuclein cytotoxicity by insulin-like growth factors. Biochem. Biophys. Res. Commun., 2009, 385, 434-438.
295. [298] Bohnen, N.I., Kotagal, V., Muller, M.L., Koeppe, R.A., Scott, P.J., Albin, R.L., Frey, K.A., Petrou, M. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat. Disord., 2014, 20(12), 1394-1398.
296. [299] Aviles-Olmos, I., Limousin, P., Lees, A., Foltynie, T. Parkinson´s disease, insulin resistance and novel agents of neuroprotection. Brain, 2013, 136, 374-384.
297. [300] Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., Tuomilehto, J. Type 2 diabetes and the risk of Parkinson´s disease. Diabetes Care, 2007, 30, 842-847.
298. [301] Schernhammer, E.; Hansen, J.; Rugbjerg, K.; Wermuth, L.; Ritz, B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care, 2011, 34(5), 1102-1108.
299. [302] Wang, L.; Zhai, Y.Q.; Xu, L.L.; Qiao, C.; Sun, X.L.; Ding, J.H.; Lu, M.; Hu, G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol., 2014, 251, 22-29.
300. [303] Choi, J.Y.; Jang, E.H.; Park, C.S.; Kang, J.H. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med., 2005, 38(6), 806-816.
301. [304] Bousquet, M.; St-Amour, I.; Vandal, M.; Julien, P.; Cicchetti, F.; Calon, F. High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis., 2012, 45(1), 529-538.
302. [305] Morris, J.K.; Bomhoff, G.L.; Stanford, J.A.; Geiger, P.C. Neurodegeneration in an animal model of Parkinson´s disease is exacerbated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 299(4), R1082-1090.
303. [306] Godau, J.; Herfurth, M.; Kattner, B.; Gasser, T.; Berg, D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2010, 81(5), 536-538.
304. [307] Kim, W., Lee, Y., McKenna, N.D., Yi, M., Simunovic, F., Wang, Y., Kong, B., Rooney, R.J., Seo, H., Stephens, R.M., Sonntag, K.C. miR-126 contributes to Parkinson´s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol. Aging, 2014, 35(7), 1712-1721.
305. [308] Pellecchia, M.T.; Santangelo, G.; Picillo, M.; Pivonello, R.; Longo, K.; Pivonello, C.; Vitale, C.; Amboni, M.; De Rosa, A.; Moccia, M.; Erro, R.; De Michele, G.; Santoro, L.; Colao, A.; Barone, P. Insulin- like growth factor-1 predicts cognitive functions at 2-year follow- up in early, drug-naive Parkinson's disease. Eur. J. Neurol., 2014, 21(5), 802-807.
306. [309] Humbert, S.; Bryson, E.A.; Cordelieres, F.P.; Connors, N.C.; Datta, S.R.; Finkbeiner, S.; Greenberg, M.E.; Saudou, F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2002, 2(6), 831-837.
307. [310] Ribeiro, M., Rosenstock, T.R., Oliveira, A.M., Oliveira, C.R., Rego, A.C. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington´s disease knock-in striatal cells. Free Rad. Biol. Med., 2014, 74, 129-144.
308. [311] Colin, E.; Regulier, E.; Perrin, V.; Durr, A.; Brice, A.; Aebischer, P.; Deglon, N.; Humbert, S.; Saudou, F. Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci., 2005, 21(6), 1478-1488.
309. [312] Yamamoto, A.; Cremona, M.L.; Rothman, J.E. Autophagymediated clearance of huntingtin aggregates triggered by the insulin- signaling pathway. J. Cell Biol., 2006, 172(5), 719-731.
310. [313] Zala, D.; Colin, E.; Rangone, H.; Liot, G.; Humbert, S.; Saudou, F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet., 2008, 17(24), 3837-3846.
311. [314] Sadagurski, M.; Cheng, Z.; Rozzo, A.; Palazzolo, I.; Kelley, G.R.; Dong, X.; Krainc, D.; White, M.F. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J. Clin. Invest., 2011, 121(10), 4070-4081.
312. [315] Duarte, A.I.; Petit, G.H.; Ranganathan, S.; Li, J.Y.; Oliveira, C.R.; Brundin, P.; Bjorkqvist, M.; Rego, A.C. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease. Exp. Neurol., 2011, 231(2), 314-319.
313. [316] Lopes, C.; Ribeiro, M.; Duarte, A.I.; Humbert, S.; Saudou, F.; Pereira de Almeida, L.; Hayden, M.; Rego, A.C. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Mol. Neurobiol., 2014, 49(3), 1126-1142.
314. [317] Browne, S. E.; Beal, M. F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox. Signal., 2006, 8(11-12), 2061-2073.
315. [318] Langston, W.; Circu, M. L.; Aw, T. Y. Insulin stimulation of gamma-glutamylcysteine ligase catalytic subunit expression increases endothelial GSH during oxidative stress: influence of low glucose. Free Radic. Biol. Med., 2008, 45(11), 1591-1599.
316. [319] Jin, Y.N.; Yu, Y.V.; Gundemir, S.; Jo, C.; Cui, M.; Tieu, K.; Johnson, G.V. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One, 2013, 8(3), e57932.